PATENT CLAIM ANALYSIS

Application Number: 16220923
Application Type: Utility
Filing Date: 2018-12
Publication Date: 2019-04
Patent Classification: ["424", "144100"]

Abstract:
The present disclosure relates to pharmaceutical compositions comprising a non-naturally occurring fusion molecule and one or more pharmaceutically acceptable carriers, formulated for oral delivery to a subject, and designed to provide for improved, effective therapies for treatment of, e.g., inflammatory diseases, autoimmune diseases, cancer, metabolic disorders, and growth deficiency disorders.

Claim (Index 7):
The pharmaceutical composition of  claim 6 , wherein the biologically active cargo is directly coupled to the C-terminus of the modified Cholix toxin.

Metadata:
- Claim Count in Document: 29.0
- Percentile: 98.0
- Lexical Diversity: 1.39535
- Patent Class: 424.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['15309177', '16207637', '16207611', '15616140', '13822435']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7777841265612802
- 35 USC 102 Novelty (BERT): 0.5661153358192728
- Combined Prediction Score: 0.7566172474870795
- Mean Citation Score: 462.81984000000006
- Max Citation Score: 541.9144
- Similarity Product: 310.2919526074886

Labels:
- Claim Label 101: 1
- Claim Label 102: 0
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 0
- Label 101 Adjusted: 1

Dataset: test